Κυριακή, 14 Απριλίου 2019

Cancers


Cancers, Vol. 11, Pages 533: The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer—Ways of Enhancing Immunotherapy Action
Cancers, Vol. 11, Pages 533: The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer—Ways of Enhancing Immunotherapy Action Cancers doi: 10.3390/cancers11040533 Authors: Evangelos Koustas Panagiotis Sarantis Georgia Kyriakopoulou Athanasios G. Papavassiliou Michalis V. Karamouzis Autophagy as a primary homeostatic and catabolic process is responsible for the degradation and recycling of proteins and cellular components. The mechanism of autophagy has a...
Cancers
1d
Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma
Abstract Purpose Lymphopenia in patients with glioblastoma (GBM) is related to treatment as well as disease progression. This retrospective study investigated the prevalence, influencing factors, recoverability, and clinical significance of lymphopenia in GBM patients treated with concomitant chemoradiotherapy (CCRT). Patients and methods A total of 219 patients...
Neuro-Oncology
1d
Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma
Abstract Osteosarcoma (OS) is an aggressive malignant tumor of the bones. Our study intended to identify and analyze potential pathogenic genes and upstream regulators for OS. We performed an integrated analysis to identify candidate pathogenic genes of OS by using three Gene Expression Omnibus (GEO) databases (GSE66673, GSE49003 and GSE37552). GO and KEGG enrichment analysis were utilized to predict the functional annotation and potential pathways of differentially expressed genes...
Pathology & Oncology Research
1d
Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis
Publication date: May 2019Source: European Journal of Cancer, Volume 113Author(s): Billal Tedbirt, Michel De Pontville, Pierre Branger, Camille Picard, Barouyr Baroudjian, Céleste Lebbé, Antoine F. Carpentier, Julie Delyon, PATIO group
European Journal of Cancer
1d
Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib
Publication date: May 2019Source: European Journal of Cancer, Volume 113Author(s): Chia-Yu Chen, Chang-Fang Chiu, Li-Yuan Bai
European Journal of Cancer
1d
Pretreatment financial toxicity predicts progression-free survival following concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer.
Related ArticlesPretreatment financial toxicity predicts progression-free survival following concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. Future Oncol. 2019 Apr 12;: Authors: Klein J, Bodner W, Garg M, Kalnicki S, Ohri N Abstract AIM: Financial toxicity (FT) describes patients' burden from out-of-pocket medical treatment costs. We studied associations between patient-reported pretreatment FT, socioeconomic status and...
Future Oncology.
1d
A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Related ArticlesA multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point? Future Oncol. 2019 Apr 12;: Authors: Villani V, Fabi A, Tanzilli A, Pasqualetti F, Lombardi G, Vidiri A, Gonnelli A, Molinari A, Cantarella M, Bellu L, Terrenato I, Carosi M, Maschio M, Telera SM, Carapella CM, Cognetti F, Paiar F, Zagonel V, Pace A Abstract AIM: This multicenter, retrospective study evaluates...
Future Oncology.
1d
Exhaled breath biopsy: a new cancer detection paradigm.
Related ArticlesExhaled breath biopsy: a new cancer detection paradigm. Future Oncol. 2019 Apr 12;: Authors: Abderrahman B PMID: 30977676 [PubMed - as supplied by publisher]
Future Oncology.
1d
Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
Related ArticlesTargeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future? Future Oncol. 2019 Apr 12;: Authors: Hindy JR, Souaid T, Kourie HR, Kattan J Abstract Bladder cancer (BC) is the most frequent cancer affecting the urinary tract. With the growing era of targeted therapies around the 2000s, many trials evaluated the efficacy of targeted therapy in advanced BC. However, no approval was given yet to any form...
Future Oncology.
1d
AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer.
Related ArticlesAIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer. Future Oncol. 2019 Apr 12;: Authors: Dirix L, Triebel F Abstract Eftilagimod alpha (IMP321), a soluble dimeric recombinant form of LAG-3, is a first-in-class antigen presenting cell activator under clinical development. By stimulating dendritic cells through MHC class II molecules, IMP321 was proven to...
Future Oncology.
1d
E-cadherin germline mutations in Māori population.
Related ArticlesE-cadherin germline mutations in Māori population. Future Oncol. 2019 Apr 12;: Authors: De Scalzi AM, Bonanni B, Galimberti V, Veronesi P, Pravettoni G, Corso G PMID: 30977389 [PubMed - as supplied by publisher]
Future Oncology.
1d
Preoperative C-reactive protein/albumin ratio predicts outcome of surgical papillary renal cell carcinoma.
Related ArticlesPreoperative C-reactive protein/albumin ratio predicts outcome of surgical papillary renal cell carcinoma. Future Oncol. 2019 Apr 12;: Authors: Gao J, Agizamhan S, Zhao X, Jiang B, Qin H, Chen M, Guo H Abstract AIM: To evaluate the prognostic values of some preoperative inflammation-based factors including C-reactive protein/albumin ratio (CRP/Alb) and platelet level in papillary renal cell carcinoma (PRCC). MATERIALS & METHODS:...
Future Oncology.
1d
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Related ArticlesIMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol. 2019 Apr 12;: Authors: Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM, Easton V, Pollex E, Deurloo R, Dent R Abstract The PD-L1 inhibitor atezolizumab received US FDA accelerated approval as treatment for programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative...
Future Oncology.
1d
The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Related ArticlesThe hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Future Oncol. 2019 Apr 12;: Authors: Onal C, Sedef AM, Kose F, Oymak E, Guler OC, Sumbul AT, Aksoy S, Akkus Yildirim B, Besen AA, Muallaoglu S, Mertsoylu H, Ozyigit G Abstract Currently, there are no predictive markers of response to abiraterone. We calculated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte...
Future Oncology.
1d
Current Immunotherapy Practices in Melanoma
Publication date: Available online 12 April 2019Source: Surgical Oncology Clinics of North AmericaAuthor(s): Luke D. Rothermel, Amod A. Sarnaik, Nikhil I. Khushalani, Vernon K. Sondak
Surgical Oncology Clinics of North America
1d
Adoptive T-Cell Therapy for Solid Malignancies
Publication date: Available online 12 April 2019Source: Surgical Oncology Clinics of North AmericaAuthor(s): Mohammad S. Jafferji, James C. Yang
Surgical Oncology Clinics of North America
1d
Future Research Goals in Immunotherapy
Publication date: Available online 12 April 2019Source: Surgical Oncology Clinics of North AmericaAuthor(s): Tyler W. Hulett, Bernard A. Fox, David J. Messenheimer, Sebastian Marwitz, Tarsem Moudgil, Michael E. Afentoulis, Keith W. Wegman, Carmen Ballesteros-Merino, Shawn M. Jensen
Surgical Oncology Clinics of North America
1d
Cancers, Vol. 11, Pages 531: Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models
Cancers, Vol. 11, Pages 531: Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models Cancers doi: 10.3390/cancers11040531 Authors: Andrea Sartori Cristina Corno Michelandrea De Cesare Eugenio Scanziani Lucia Minoli Lucia Battistini Franca Zanardi Paola Perego Ovarian carcinoma, the most lethal gynecological cancer, is characterized by late diagnosis, with drug resistance limiting the...
Cancers
1d
Existential Loneliness and the Importance of Addressing Sexual Health in People with Advanced Cancer in Palliative Care
Psycho-Oncology
1d
Effects of reallocating sedentary time with physical activity on quality of life indicators in breast cancer survivors
AbstractObjectivesPhysical activity is associated with better quality of life (QOL) among breast cancer survivors. However, it is unknown the extent to which time spent sedentary or replacing this time with active behaviors may affect QOL. Our aim was to determine the effect of substituting time between sedentary and active behaviors on QOL indicators in breast cancer survivors.MethodsAn isotemporal substitution approach was used to examine the associations of reallocating time to sedentary...
Psycho-Oncology
1d


--
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00306932607174,00302841026182,alsfakia@gmail.com

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις